<DOC>
	<DOCNO>NCT00872950</DOCNO>
	<brief_summary>The purpose study determine effectiveness adverse effect 3,4-diaminopyridine treatment Lambert-Eaton Myasthenic Syndrome ( LEMS ) Congenital Myasthenic Syndromes ( CMS ) .</brief_summary>
	<brief_title>3,4-Diaminopyridine Use Lambert-Eaton Myasthenic Syndrome ( LEMS ) Congenital Myasthenic Syndromes ( CMS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>Myasthenic Syndromes , Congenital</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>LEMS diagnosis OR Pre Post Synaptic CMS diagnosis 18 year old Females must negative pregnancy test willing practice effective form birth control No prolong QT syndrome indicate baseline EKG Known sensitivity 3,4DIAMINOPYRIDINE History seizure and/or severe asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>LEMS</keyword>
	<keyword>CMS</keyword>
	<keyword>3,4 DIAMINOPYRIDINE</keyword>
	<keyword>3,4 DAP</keyword>
</DOC>